Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects

NCT02094521 ↗

Phase 1 Completed 122 enrolled Novo Nordisk A/S

RandomizedSingle-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of the trial is to evaluate the optimal dosing conditions for GLP-1 analogue NNC0113-0987 when administered orally in healthy male subjects.

Timeline

Start: 2014-03
Primary completion: 2014-07
Completion: 2014-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NNC0113-0987	Unknown	10 mg	Oral

Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects

Summary

Timeline

Drugs

Indications